Publications

Nature

The shieldin complex mediates 53BP1-dependent DNA repair.

01-08-2018

The Journal of pathology

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

01-08-2018

Open biology

Mouse models in the era of large human tumour sequencing studies.

01-08-2018

Cancer cell

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

11-06-2018

British journal of cancer

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.

01-06-2018

Molecular oncology

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.

01-06-2018

Nucleic acids research

Easy quantification of template-directed CRISPR/Cas9 editing.

01-06-2018

Cell reports

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

15-05-2018

Annals of oncology : official journal of the European Society for Medical Oncology

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

01-05-2018

Cell reports

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

03-04-2018

Cancer discovery

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

01-04-2018

Oncogene

Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.

01-03-2018

Nature methods

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

01-02-2018

Laboratory investigation; a journal of technical methods and pathology

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

01-01-2018

Clinical cancer research : an official journal of the American Association for Cancer Research

Selected Alkylating Agents Can Overcome Drug Tolerance of G₀-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

15-11-2017

Nature cell biology

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

01-11-2017

Cancer research

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

01-11-2017

Oncotarget

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

20-10-2017

EMBO molecular medicine

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

01-10-2017

Oncotarget

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

22-09-2017

Oncotarget

Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.

15-08-2017

Nature genetics

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

01-08-2017

Nature communications

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

17-07-2017

Nucleic acids research

Identifying transposon insertions and their effects from RNA-sequencing data.

07-07-2017

Oncogene

p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.

27-04-2017

Nature reviews. Cancer

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

01-04-2017

The Journal of pathology

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

01-03-2017

EMBO molecular medicine

Genetically engineered mouse models in oncology research and cancer medicine.

01-02-2017

Journal of mammary gland biology and neoplasia

p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice.

01-12-2016

Nature cell biology

Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours.

01-12-2016

Cold Spring Harbor symposia on quantitative biology

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.

07-11-2016

Journal of the National Cancer Institute

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

01-11-2016

Cancer research

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

15-10-2016

Oncotarget

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.

27-09-2016

Cell reports

PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.

23-08-2016

J Clin Invest: The Journal of clinical investigation

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

25-07-2016

Nature

Replication fork stability confers chemoresistance in BRCA-deficient cells.

21-07-2016

Genes & development

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.

15-06-2016

Nature

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

02-06-2016

Cancer research

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

01-05-2016

Molecular cell

HELB Is a Feedback Inhibitor of DNA End Resection.

04-02-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.

01-01-2016

Nature protocols

Using the GEMM-ESC strategy to study gene function in mouse models.

01-11-2015

Annals of oncology : official journal of the European Society for Medical Oncology

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.

01-10-2015

Oncogene

FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.

24-09-2015

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

01-09-2015

Pain

Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancer.

01-08-2015

Proceedings of the National Academy of Sciences of the United States of America

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

07-07-2015

Nature

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

18-06-2015

Nature

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

28-05-2015

The shieldin complex mediates 53BP1-dependent DNA repair.

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

Mouse models in the era of large human tumour sequencing studies.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.

Easy quantification of template-directed CRISPR/Cas9 editing.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

Identifying transposon insertions and their effects from RNA-sequencing data.

p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

Genetically engineered mouse models in oncology research and cancer medicine.

p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice.

Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours.

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.

PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

Replication fork stability confers chemoresistance in BRCA-deficient cells.

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

HELB Is a Feedback Inhibitor of DNA End Resection.

Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.

Using the GEMM-ESC strategy to study gene function in mouse models.

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.

FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancer.

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

This site uses cookies

Selected Alkylating Agents Can Overcome Drug Tolerance of G₀-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.